Nucleix Stock
Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests.
Sign up today and learn more about Nucleix Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Nucleix Stock
Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Its sensitive and specific tests are based on identification of subtle changes in methylation patterns. Nucleix offers a urine test for monitoring of bladder cancer called Bladder EpiCheck and a blood test for early detection of lung cancer called Lung EpiCheck. Adam Wasserstrom, Danny Frumkin, and Elon Ganor founded it in 2008, with its headquarters in Rehovot in Israel.
Funding History
| January 2015 | $50K |
|---|---|
| May 2016 | $3.0M |
| July 2018 | $2.5M |
| April 2021 | $55.0M |
| January 2022 | $22.0M |
Management
Co-founder, VP Software & Analytics
Adam Wasserstrom
VP Research & Co-founder
Danny Frumkin
Chief Executive Officer
Chris Hibberd
Member of Board of Directors
Dan J. Gelvan
Chief Financial Officer
W. Todd Myers
Executive Chairman
Chris Hibberd
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
